Page 278 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 278
Viral Hepatitis: Hepatitis C - Clinical (New Compounds, Resistance) (Cont.)
P0904 RG-101, A NOVEL GALNAC-CONJUGATED INHIBITOR OF
MICRORNA-122, DEMONSTRATES SIGNIFICANT VIRAL
LOAD REDUCTION AND REDUCES LIVER STEATOSIS
IN HUMAN HEPATOCYTE CHIMERIC MICE INFECTED
WITH GENOTYPE 1A OR HARD-TO-TREAT GENOTYPE 3A
HEPATITIS C VIRUS (HCV)
Steven Neben, Kai Liu, Jia Tay, Nelson Chau,Yoshio Morikawa,
Balkrishnan Bhat, Neil Gibson*, The United States
P0905 NO SIGNIFICANT INTERACTION AMONG OMBITASVIR/
PARITAPREVIR/RITONAVIR ± DASABUVIR AND
SOFOSBUVIR
Jennifer King*, Sandeep Dutta, Daniel Cohen, Thomas Podsadecki,
Bifeng Ding, Walid Awni, Rajeev Menon, The United States
P0906 INHIBITION OF HCV REPLICATION BY CCR5 BLOCKADE
WITH CENICRIVIROC AND MARAVIROC
Kenneth E. Sherman*, Ling Kong, Jason T. Blackard, The United States
ePOSTERS P0907 PHARMACOKINETICS, PHARMACODYNAMICS, AND
TOXICITY PROFILE OF RG-101, A NOVEL GALNAC-
CONJUGATED HEPATOCYTE-TARGETNG INHIBITOR
OF MICRORNA-122, IN RODENTS AND CYNOMOLGUS
MONKEYS
Steven Neben, Kai Liu, Cindy Berman, Jia Tay, Christine Esau,
Robert Kaiser, Bradley Wahle, Nelson Chau, Balkrishnan Bhat,
Neil Gibson*, The United States
P0908 ADHERENCE TO OMBITASVIR/PARITAPREVIR/R,
DASABUVIR, AND RIBAVIRIN IS >98% IN THE SAPPHIRE-I
AND SAPPHIRE-II TRIALS
Tarek Hassanein*, Stuart Roberts, Stephen D. Shafran, Mihály Makara,
Michael Bennett, Beat Müllhaupt, Fred Poordad, Stephen Ryder,
Adrian M. Di Bisceglie, Bo Fu, Eoin Coakley, Barbara H. McGovern,
Graham R. Foster, The United States
P0909 ANALYSIS OF NATURAL RESISTANCE PROFILE TO NS5A
RELICATION COMPLEX INHIBITORS IN DIFFERENT
HEPATITIS C GENOTYPES
Sabrina Bagaglio*, Emanuela Messina, Marco Merli, Hamid Hasson,
Adriano Lazzarin, Caterina Uberti-Foppa, Giulia Morsica, Italy
278 The International Liver Congress™ 2015 • ILC Programme
P0904 RG-101, A NOVEL GALNAC-CONJUGATED INHIBITOR OF
MICRORNA-122, DEMONSTRATES SIGNIFICANT VIRAL
LOAD REDUCTION AND REDUCES LIVER STEATOSIS
IN HUMAN HEPATOCYTE CHIMERIC MICE INFECTED
WITH GENOTYPE 1A OR HARD-TO-TREAT GENOTYPE 3A
HEPATITIS C VIRUS (HCV)
Steven Neben, Kai Liu, Jia Tay, Nelson Chau,Yoshio Morikawa,
Balkrishnan Bhat, Neil Gibson*, The United States
P0905 NO SIGNIFICANT INTERACTION AMONG OMBITASVIR/
PARITAPREVIR/RITONAVIR ± DASABUVIR AND
SOFOSBUVIR
Jennifer King*, Sandeep Dutta, Daniel Cohen, Thomas Podsadecki,
Bifeng Ding, Walid Awni, Rajeev Menon, The United States
P0906 INHIBITION OF HCV REPLICATION BY CCR5 BLOCKADE
WITH CENICRIVIROC AND MARAVIROC
Kenneth E. Sherman*, Ling Kong, Jason T. Blackard, The United States
ePOSTERS P0907 PHARMACOKINETICS, PHARMACODYNAMICS, AND
TOXICITY PROFILE OF RG-101, A NOVEL GALNAC-
CONJUGATED HEPATOCYTE-TARGETNG INHIBITOR
OF MICRORNA-122, IN RODENTS AND CYNOMOLGUS
MONKEYS
Steven Neben, Kai Liu, Cindy Berman, Jia Tay, Christine Esau,
Robert Kaiser, Bradley Wahle, Nelson Chau, Balkrishnan Bhat,
Neil Gibson*, The United States
P0908 ADHERENCE TO OMBITASVIR/PARITAPREVIR/R,
DASABUVIR, AND RIBAVIRIN IS >98% IN THE SAPPHIRE-I
AND SAPPHIRE-II TRIALS
Tarek Hassanein*, Stuart Roberts, Stephen D. Shafran, Mihály Makara,
Michael Bennett, Beat Müllhaupt, Fred Poordad, Stephen Ryder,
Adrian M. Di Bisceglie, Bo Fu, Eoin Coakley, Barbara H. McGovern,
Graham R. Foster, The United States
P0909 ANALYSIS OF NATURAL RESISTANCE PROFILE TO NS5A
RELICATION COMPLEX INHIBITORS IN DIFFERENT
HEPATITIS C GENOTYPES
Sabrina Bagaglio*, Emanuela Messina, Marco Merli, Hamid Hasson,
Adriano Lazzarin, Caterina Uberti-Foppa, Giulia Morsica, Italy
278 The International Liver Congress™ 2015 • ILC Programme
